ritlecitinib
Showing 1 - 9 of 9
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo Trial (Ritlecitinib, Placebo)
Not yet recruiting
- Stable Nonsegmental Vitiligo
- Active Nonsegmental Vitiligo
- Ritlecitinib
- Placebo
- (no location specified)
Oct 2, 2023
CTCL, Mycosis Fungoides, Sezary Syndrome Trial in New York (Ritlecitinib)
Recruiting
- CTCL
- +2 more
- Ritlecitinib
-
New York, New YorkIcahn School of Medicine at Mount Sinai
May 18, 2023
Healthy Volunteers, Adult, Pharmacokinetics Trial in Brussels (Ritlecitinib)
Not yet recruiting
- Healthy Volunteers
- +2 more
- Ritlecitinib
-
Brussels, Bruxelles-capitale, Région DE, BelgiumBrussels Clinical Research Unit
May 1, 2023
Celiac Disease Trial (Ritlecitinib, Placebo, Gluten)
Not yet recruiting
- Celiac Disease
- Ritlecitinib
- +2 more
- (no location specified)
Nov 23, 2022
Healthy Participants Trial in New Haven (ritlecitinib)
Completed
- Healthy Participants
- ritlecitinib
-
New Haven, ConnecticutNew Haven Clinical Research Unit
Jan 20, 2022
Healthy Volunteers Trial in New Haven (Ritlecitinib, Tolbutamide)
Completed
- Healthy Volunteers
- Ritlecitinib
- Tolbutamide
-
New Haven, ConnecticutNew Haven Clinical Research Unit
Jan 18, 2022
Non-segmental Vitiligo (Both Active and Stable Vitiligo) Trial in Canada, Japan, United States (Ritlecitinib, Placebo)
Recruiting
- Non-segmental Vitiligo (Both Active and Stable Vitiligo)
- Ritlecitinib
- Placebo
-
Huntington Beach, California
- +16 more
Jan 18, 2023
Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)
Not yet recruiting
- Diabetes Mellitus, Type 1
- Abrocitinib 200 MG Oral Tablet
- +2 more
- (no location specified)
Feb 21, 2023
Healthy Participants Trial in New Haven (Caffeine, Ritlecitinib)
Completed
- Healthy Participants
- Caffeine
- Ritlecitinib
-
New Haven, ConnecticutNew Haven Clinical Research Unit
Mar 17, 2021